LUND, Sweden, April 29, 2024 /PRNewswire/ --Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

瑞典隆德，2024年4月29日/PRNewswire/--Immunovia（STO:IMMNOV），一家寻求通过早期检测提高胰腺癌生存率的诊断公司，今天宣布任命丽莎·福特博士为临床实验室主任。

As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners, especially Proteomedix..

作为临床实验室主任，福特博士将领导实验室运营以及Immunovia下一代测试的研究和开发。她的主要职责是配置、发展和监督实验室团队；质量保证和法规遵从性；并促进与外部合作伙伴（尤其是Proteomedix）的合作与沟通。。

Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests. She has extensive experience overseeing clinical and bioanalytical laboratories and associated quality systems, managing clinical assay development, validation projects, quality improvement and laboratory personnel. .

Lisa通过研究、开发、验证（临床和分析）和诊断测试的实施，拥有领导实验室项目团队的20多年经验。她拥有监督临床和生物分析实验室及相关质量系统的丰富经验，管理临床分析开发，验证项目，质量改进和实验室人员。。

'We are very excited to appoint Lisa as Lab Director for Immunovia. Lisa brings deep expertise in creating lab-developed tests (LDTs) and leading diagnostic labs. As a consultant to Immunovia over the last few months, Lisa has made fantastic contributions to our R&D efforts. She is very bright, analytical, thorough, and practical', says Jeff Borcherding, CEO and President of Immunovia..

“我们很高兴任命丽莎为Immunovia的实验室主任。Lisa在创建实验室开发测试（LDT）和领先的诊断实验室方面拥有丰富的专业知识。在过去的几个月里，作为Immunovia的顾问，Lisa为我们的研发工作做出了巨大贡献。Immunovia首席执行官兼总裁杰夫·博切尔丁（JeffBorcherding）表示：“她非常聪明、善于分析、彻底且务实。”。。

Lisa holds a Ph.D. from Duke University in Bioorganic Chemistry and a B.S. from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.

丽莎拥有博士学位。D、 杜克大学生物有机化学学士和加利福尼亚大学化学学士，并获得美国生物分析委员会的高复杂性临床实验室主任认证。

For more information, please contact:

有关更多信息，请联系：

Jeff Borcherding

Jeff Borcherding

CEO and President

首席执行官兼总裁

jeff.borcherding@immunovia.com

jeff.borcherding@immunovia.com

Karin Almqvist Liwendahl

Karin Almqvist Liwendahl

Chief Financial Officer

首席财务官

karin.almqvist.liwendahl@immunovia.com

karin.almqvist.liwendahl@immunovia.com

+46 709 11 56 08

+46 709 11 56 08

Immunovia in brief

Immunovia简介

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer..

Immunovia AB是一家诊断公司，其使命是通过早期发现提高胰腺癌患者的生存率。Immunovia专注于开发和商业化简单的基于血液的检测方法，以检测表明高危人群已患胰腺癌的蛋白质和抗体。。

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

Immunovia与医疗保健提供者，领先专家和患者倡导团体合作并参与其中，使其测试可用于胰腺癌风险增加的个人。

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

美国是世界上最大的胰腺癌检测市场。该公司估计，在美国，有180万人患有胰腺癌的高风险，可以从年度监测测试中受益。

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

Immunovia的股票（IMMNOV）在纳斯达克斯德哥尔摩上市。有关更多信息，请访问 www.immunovia.com

This information was brought to you by Cision http://news.cision.com

此信息由Cision提供给您http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-appoints-dr--lisa-ford-as-clinical-laboratory-director,c3969778

https://news.cision.com/immunovia-ab/r/immunovia-appoints-dr--lisa-ford-as-clinical-laboratory-director，c3969778

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/13121/3969778/2767224.pdf

https://mb.cision.com/Main/13121/3969778/2767224.pdf

Press release (PDF)

新闻稿（PDF）

View original content:https://www.prnewswire.com/news-releases/immunovia-appoints-dr-lisa-ford-as-clinical-laboratory-director-302129990.html

查看原始内容：https://www.prnewswire.com/news-releases/immunovia-appoints-dr-lisa-ford-as-clinical-laboratory-director-302129990.html

SOURCE Immunovia AB

来源Immunovia AB

Company Codes: Bloomberg:IMMNOV@SS, ISIN:SE0006091997, RICS:IMMNOV.ST

公司代码：彭博社：IMMNOV@SS，ISIN:SE0006091997，RICS:IMMNOV。圣